Multiple Myeloma with t(4;14) gene change study
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial is looking at stored tumor samples (FFPE blocks) from people with multiple myeloma that has a specific gene change called t(4;14). The goal is to learn more about this type of myeloma, which may help in developing better treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have multiple myeloma with a specific gene change called t(4;14) translocation.
- A stored tumor sample (FFPE block) from a biopsy or surgery is available.
- Your diagnosis was made within the last 10 years.
- Your medical records (test results and follow-up information) are available.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is collecting and testing stored tissue samples from people with extramedullary myeloma (myeloma that has spread outside the bone marrow). The goal is to better understand this type of myeloma and find potential treatment targets.
This trial studies myeloma (and closely related blood disorders) by using extra blood or bone marrow samples for lab research. It aims to help discover new ways to understand or treat myeloma.
This study looks at how multiple myeloma (a bone marrow cancer) changes over time, especially why it becomes resistant to treatment or comes back. It may help researchers learn what drives relapse and could lead to better future treatments.
This study tests a combination of four cancer-fighting drugs (isatuximab, iberdomide, bortezomib, and dexamethasone) followed by a stem cell transplant for people newly diagnosed with multiple myeloma. The goal is to see if this approach can help patients live longer and control their disease better.
This trial tests an experimental therapy called CT071 for people with newly diagnosed, high-risk multiple myeloma. It aims to see if this treatment can help control the disease in people who have certain aggressive features.
This Phase 2/3 trial tests whether matching treatment choices to a patient’s myeloma risk pattern (using blood and scan results) improves outcomes. It is for people with newly diagnosed, untreated, symptomatic multiple myeloma who may also receive transplant-related treatment.
Hear when a new Multiple Myeloma and Malignant Plasma Cell Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.